M4 Receptor Antagonist Compounds for Selective Neurological Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing muscarinic receptor antagonists lack selectivity for the M4 subtype, leading to undesirable side effects and limited therapeutic efficacy in treating neurological disorders.
Innovation Solution
Development of compounds, such as 2-(1-benzylpiperidin-4-yl)ethyl (2R,6S)-2,6-dimethyl-4-[5-(trifluoromethyl)pyrazin-2-yl]piperazine-1-carboxylate, with enhanced selectivity for the M4 receptor, formulated as pharmaceutical compositions to treat neurological diseases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If classical muscarinic receptor antagonists (e.g., atropine, scopolamine, QNB) are used, then broad anticholinergic coverage is achieved, but selectivity for M4 receptor is lost leading to use-limiting side effects
Solution Approach 1:
The patent applies local quality by designing compounds with specific molecular features (e.g., piperazine ring with specific substituents, piperidine moiety) that confer selective affinity for M4 receptor over other muscarinic subtypes. The structural modifications create localized interactions with M4 receptor binding site that are distinct from M1, M2, M3, and M5 receptors, thereby achieving subtype-specific antagonism and reducing off-target side effects.
Solution Approach 2:
The patent employs parameter changes by systematically varying molecular parameters such as substituent groups on the piperazine ring (e.g., trifluoromethylpyrazinyl group), stereochemistry (R/S configurations), and linker chain lengths to optimize M4 selectivity. These parameter adjustments fine-tune the binding affinity and selectivity profile, enabling differentiation between M4 and other muscarinic receptors while maintaining therapeutic efficacy.
2Ease of operation
If non-selective anticholinergic drugs are used to treat extrapyramidal symptoms, then symptom relief is achieved, but cognitive impairment and gastrointestinal dysfunction occur due to M1, M2, and M3 antagonism
Solution Approach 1:
The patent applies segmentation by separating the therapeutic effect from the harmful effects through subtype-selective antagonism. Instead of blocking all muscarinic receptors, the compounds selectively target M4 receptor in the striatum, segmenting the anticholinergic effect from cognitive and gastrointestinal functions that involve M1, M2, and M3 receptors. This segmentation allows symptom relief without the debilitating side effects of non-selective antagonists.
Solution Approach 2:
The patent uses M4-selective compounds as intermediaries that specifically modulate striatal acetylcholine release without affecting other muscarinic pathways. These compounds act as selective mediators between the therapeutic goal (treating extrapyramidal symptoms) and the avoidance of harmful effects, by engaging only the M4 receptor subtype that mediates the pathological processes in Parkinson's disease and related disorders.
3Object-affected harmful factors
If M4-selective compounds are developed, then side effects are reduced, but drug-like properties and pharmacokinetic profile require optimization
Solution Approach 1:
The patent applies composite materials by combining multiple structural elements (piperazine ring, piperidine moiety, aromatic substituents, linker chains) with specific stereochemical configurations to create compounds that simultaneously achieve M4 selectivity and favorable pharmacokinetic properties. The composite molecular structure integrates features that confer both target selectivity and drug-like characteristics including metabolic stability, solubility, and membrane permeability.
Data Source
AI summary
Provided herein are compounds of the following Formula (I): or a pharmaceutically acceptable salt thereof. Methods for treating a diseases, disorders, or symptom by antagonizing muscarinic receptors, including specifically antagonizing muscarinic receptor 4 (M4), are also provided.